The University of Oxford is set to begin a trial combining Covid-19 vaccines from AstraZeneca and Pfizer that could enable greater flexibility in the use of scarce supplies globally.


The university will begin recruiting 820 participants over 50 years of age across eight UK sites this week, according to a statement Thursday.


The Astra and Pfizer vaccines will be given in different orders and with two dosing intervals, four and 12 weeks apart.


The trial will allow researchers to see whether two shots of different vaccines produce better or worse results than two doses of the same product. The study could be key to relieving pressure on individual vaccine makers to deliver shots if they run into manufacturing difficulties.


Mixing vaccines to create an enhanced immune response is common for inoculations targeting diseases such as hepatitis A and B.


Combining shots can boost the immune response because the second shot won’t be limited by any immunity the body has built up to the platform delivering the first vaccine.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor



Source link